1057 related articles for article (PubMed ID: 16189291)
1. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
2. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
3. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
[TBL] [Abstract][Full Text] [Related]
5. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
7. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
9. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis.
Jonassen TE; Nielsen S; Christensen S; Petersen JS
Am J Physiol; 1998 Aug; 275(2):F216-25. PubMed ID: 9691010
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans.
Shimizu K
Clin Nephrol; 2003 Mar; 59(3):164-73. PubMed ID: 12653258
[TBL] [Abstract][Full Text] [Related]
11. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
Al Therwani S; Rosenbæk JB; Mose FH; Bech JN; Pedersen EB
BMC Nephrol; 2017 Mar; 18(1):86. PubMed ID: 28288570
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Takada T; Masaki T; Hoshiyama A; Toki T; Kamata Y; Shichiri M
Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
[TBL] [Abstract][Full Text] [Related]
13. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
14. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
[TBL] [Abstract][Full Text] [Related]
15. Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
Al Therwani S; Mose FH; Jensen JM; Bech JN; Pedersen EB
BMC Nephrol; 2014 Jun; 15():100. PubMed ID: 24965902
[TBL] [Abstract][Full Text] [Related]
16. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
[TBL] [Abstract][Full Text] [Related]
17. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
[TBL] [Abstract][Full Text] [Related]
18. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
19. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
[TBL] [Abstract][Full Text] [Related]
20. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
